Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region

International Journal of Gynecology and Obstetrics

Volumn 102, Issue 3, 2008, Pages 275-283

  Tay, E H ^a   Garland, S ^b   Tang, G ^c   Nolan, T ^b   Huang, L M ^d   Orloski, L ^e   Lu, S ^e   Barr, E ^e  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; Clinical trial; Genital warts; Human papillomavirus; Prophylactic vaccine

Indexed keywords

HPV 6/11/16/18 VACCINE; PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BODY TEMPERATURE; CIGARETTE SMOKING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; INCIDENCE; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SUICIDAL IDEATION; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRUS LIKE AGENT; WART VIRUS;

EID: 49349084203     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijgo.2008.03.021     Document Type: Article

References (25)

1. Agosti J.M., and Goldie S.J. Introducing HPV vaccine in developing countries: key challenges and issues. N Engl J Med 356 19 (2007) 1908-1910
2. Moore M.A., and Tajima K. Cervical cancer in the Asian Pacific: epidemiology, screening and treatment. Asian Pac. J. Cancer 5 4 (2004) 349-361
3. Lacey C.J., Lowndes C., and Shah K. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 suppl 3 (2006) S35-S41
4. Muñoz N., Castellsague X., de Gonzalez A.B., and Gissman L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24 suppl 3 (2006) S1-S10
5. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87 11 (1995) 796-802
6. Clifford G., Franceschi S., Diaz M., Munoz N., and Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 suppl 3 (2006) S26-S34
7. Chen C.A., Liu C.Y., Chou H.H., Chou C.Y., Ho C.M., Twu N.F., et al. The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: a Taiwan Cooperative Oncologic Group Study. Int J Gynecol Cancer 16 5 (2006) 1801-1808
8. Clifford G.M., Smith J.S., Plummer M., Münoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 1 (2003) 63-73
9. Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 9490 (2005) 991-998
10. Lai C.H., Huang H., Hsueh S., Chao A., Lin C., Huang S., et al. Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer 120 9 (2007) 1999-2006
11. Lin H., Ma Y.Y., Moh J.S., Ou Y.C., Shen S.Y., and ChangChien C.C. High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. Gynecol Oncol 101 1 (2006) 40-45
12. Lo K.W., Wong Y.F., Chan M.K., Li J.C., Poon J.S., Wang V.W., et al. Prevalence of human papillomavirus in cervical cancer: a multicenter study in China. Int J Cancer 100 6 (2002) 327-331
13. Sriamporn S., Snijders P.J., Pientong C., Pisani P., Ekalaksananan T., Meijer C.J., et al. Human papillomavirus and cervical cancer from a prospective study in Khon Kaen, Northeast Thailand. Int J Gynecol Cancer 16 1 (2006) 266-269
14. Stevens M.P., Tabrizi S.N., Quinn M.A., and Garland S.M. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. Int J Gynecol Cancer 16 3 (2006) 1017-1024
15. Chang C.H., Chen T.H., Hsu R.C., Chou P.H., Yang J.J., and Hwang G.Y. The prevalence of HPV-18 and variants of E6 gene isolated from cervical cancer patients in Taiwan. J Clin Virol 32 1 (2005) 33-37
16. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 19 (2007) 1915-1927
17. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 19 (2007) 1928-1943
18. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 5 (2006) 2135-2145
19. Reisinger K.S., Block S.L., Lazcano-Ponce E., Samakoses R., Esser M.T., Erick J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26 3 (2007) 201-209
20. Miettinen O., and Nurminen M. Comparative analysis of two rates. Stat Med 4 2 (1985) 213-226
21. Lai H.C., Peng M., Hieh S., Yu C., Chang C., Lin Y.W., et al. Differential viral loads of human papillomavirus 16 and 58 infections in the spectrum of cervical carcinogenesis. Int J Gynecol Cancer 16 2 (2006) 730-735
22. Sukvirach S., Smith J.S., Tunsakul S., Muñoz N., Kesararat V., Opasatian O., et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 187 8 (2003) 1246-1256
23. Ferlay J., Bray F., Pisani P., and Parkin D.M. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5, Version 2.0 (2004), IARC Press, Lyon, France
24. Sheary B., and Dayan L. Cervical screening and human papillomavirus. Aust Fam Physician 34 7 (2005) 578-580
25. Denny L., Quinn M., and Sankaranarayanan R. Chapter 8: screening for cervical cancer in developing countries. Vaccine 24 supl 3 (2006) S71-S77